Mario Mauri

Dr. Mario Mauri

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
CBClaudia Balducci
Claudia Balducci
SMSimona Mancini
Simona Mancini
SMStefania Minniti
Stefania Minniti
PVPietro La Vitola
Pietro La Vitola
MZMargherita Zotti
Margherita Zotti
FRFrancesca Re
Francesca Re
Alzheimer's disease is characterized by the accumulation and deposition of plaques of β-amyloid (Aβ) peptide in the brain. Given its pivotal role, new therapies targeting Aβ are in demand. We rationally designed liposomes targeting the brain and promoting the disaggregation of Aβ assemblies and evaluated their efficiency in reducing the Aβ burden in Alzheimer's disease mouse models. Liposomes were bifunctionalized with a peptide derived from the apolipoprotein-E receptor-binding domain for blood–brain barrier targeting and with phosphatidic acid for Aβ binding. Bifunctionalized liposomes display the unique ability to hinder the formation of, and disaggregate, Aβ assembliesin vitro(EM experiments). Administration of bifunctionalized liposomes to APP/presenilin 1 transgenic mice (aged 10 months) for 3 weeks (three injections per week) decreased total brain-insoluble Aβ1–42(−33%), assessed by ELISA, and the number and total area of plaques (−34%) detected histologically. Also, brain Aβ oligomers were reduced (−70.5%), as assessed by SDS-PAGE. Plaque reduction was confirmed in APP23 transgenic mice (aged 15 months) either histologically or by PET imaging with [11C]Pittsburgh compound B (PIB). The reduction of brain Aβ was associated with its increase in liver (+18%) and spleen (+20%). Notably, the novel-object recognition test showed that the treatment ameliorated mouse impaired memory. Finally, liposomes reached the brain in an intact form, as determined by confocal microscopy experiments with fluorescently labeled liposomes. These data suggest that bifunctionalized liposomes destabilize brain Aβ aggregates and promote peptide removal across the blood–brain barrier and its peripheral clearance. This all-in-one multitask therapeutic device can be considered as a candidate for the treatment of Alzheimer's disease.

1 April 2012 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
MMMario Mauri
Mario Mauri
DLDaniela Lentini
Daniela Lentini
MGMarta Gravati
Marta Gravati
DFDana Foudah
Dana Foudah
GBGerardo Rosario Biella
Gerardo Rosario Biella
SCSilvia Coco
Silvia Coco

7 July 2015 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
SRSara Redaelli
Sara Redaelli
PPPietro Perini
Pietro Perini
MCMonica Ceccon
Monica Ceccon
RPRocco Piazza
Rocco Piazza
RRRoberta Rigolio
Roberta Rigolio
CGCarlo Gambacorti-Passerini
Carlo Gambacorti-Passerini
Bosutinib is a recently approved ABL inhibitor. In spite of the well-documented effectiveness of BCR-ABL inhibitors in treating chronic myeloid leukemia, development of resistance is a continuous clinical challenge. Transporters that facilitate drug uptake and efflux have been proposed as one potential source of resistance to tyrosine kinase inhibitor treatment. Our aim was to determine which carriers are responsible for bosutinib transport. K562S cells overexpressing the drug transporters ABCB1, ABCG2, and SLC22A1 were generated, characterized and used in proliferation assay and intracellular uptake and retention assay (IUR). In vivo experiments were performed in nude mice injected with K562S, K562DOX cells (overexpressing ABCB1), and K562DOX silenced for ABCB1 (K562DOX/sh P-GP). The IUR assay using C-14 bosutinib showed that only ABCB1 was responsible for active bosutinib transport. K562DOX cells showed the lowest intracellular level of bosutinib, while K562DOX cells treated with the ABCB1 inhibitor verapamil showed intracellular bosutinib levels comparable with parental K562S. Proliferation assays demonstrated that K562DOX are resistant to bosutinib treatment while verapamil is able to restore the sensitivity to the drug. Nude mice injected with K562DOX and treated with bosutinib showed very limited response and quickly relapsed after stopping treatment while K562S as well as K562DOX/sh P-GP remained tumor-free. Our data suggest that the analysis of ABCB1 expression levels might help determine treatment options for patients exhibiting resistance to bosutinib.

1 January 2017 in Biochemical Pharmacology
Verified
Journal Article
Open access
VCValérie Capra
Valérie Capra
MMMario Mauri
Mario Mauri
FGFrancesca Guzzi
Francesca Guzzi
MBMarta Busnelli
Marta Busnelli
MAMaria Rosa Accomazzo
Maria Rosa Accomazzo
GRGianenrico Rovati
Gianenrico Rovati
Thromboxane A2 is a potent mediator of inflammation and platelet aggregation exerting its effects through the activation of a G protein-coupled receptor (GPCR), termed TP. Although the existence of dimers/oligomers in Class A GPCRs is widely accepted, their functional significance still remains controversial. Recently, we have shown that TPα and TPβ homo-/hetero-dimers interact through an interface of residues in transmembrane domain 1 (TM1) whose disruption impairs dimer formation. Here, biochemical and pharmacological characterization of this dimer deficient mutant (DDM) in living cells indicates a significant impairment in its response to agonists. Interestingly, two single loss-of-function TPα variants, namely W29C and N42S recently identified in two heterozygous patients affected by bleeding disorders, match some of the residues mutated in our DDM. These two naturally occurring variants display a reduced potency to TP agonists and are characterized by impaired dimer formation in transfected HEK-293T cells. These findings provide proofs that lack of homo-dimer formation is a crucial process for reduced TPα function in vivo, and might represent one molecular mechanism through which platelet TPα receptor dysfunction affects the patient(s) carrying these mutations.

7 January 2011 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
FFFrancesca Fanelli
Francesca Fanelli
MMMario Mauri
Mario Mauri
VCValérie Capra
Valérie Capra
FRFrancesco Raimondi
Francesco Raimondi
FGFrancesca Guzzi
Francesca Guzzi
MPMarco Parenti
Marco Parenti

1 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GAGiulia Arosio
Giulia Arosio
GSGeeta Geeta Sharma
Geeta Geeta Sharma
MVMatteo Villa
Matteo Villa
MMMario Mauri
Mario Mauri
ICIlaria Crespiatico
Ilaria Crespiatico
LMLuca Mologni
Luca Mologni
Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is a subtype of non-Hodgkin lymphoma characterized by expression of the oncogenic NPM/ALK fusion protein. When resistant or relapsed to front-line chemotherapy, ALK+ ALCL prognosis is very poor. In these patients, the ALK inhibitor crizotinib achieves high response rates, however 30–40% of them develop further resistance to crizotinib monotherapy, indicating that new therapeutic approaches are needed in this population. We here investigated the efficacy of upfront rational drug combinations to prevent the rise of resistant ALCL, in vitro and in vivo. Different combinations of crizotinib with CHOP chemotherapy, decitabine and trametinib, or with second-generation ALK inhibitors, were investigated. We found that in most cases combined treatments completely suppressed the emergence of resistant cells and were more effective than single drugs in the long-term control of lymphoma cells expansion, by inducing deeper inhibition of oncogenic signaling and higher rates of apoptosis. Combinations showed strong synergism in different ALK-dependent cell lines and better tumor growth inhibition in mice. We propose that drug combinations that include an ALK inhibitor should be considered for first-line treatments in ALK+ ALCL.